Navigation Links
Anthera Announces First Quarter 2013 Financial Report and Conference Call
Date:5/3/2013

HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will release its first quarter 2013 financial report after market close on Monday, May 13th. Anthera will host a Corporate Update conference call on May 20th, 2013.

Conference Call Access:
Date:   Monday, May 20th, 2013
Time:   5:00 pm Eastern Time

Domestic Dial-in:        (877)312-8807
International Dial-in:   (253)237-1190
Conference ID:           64577060

To access the 24-hour audio replay, U.S. and Canadian participants may dial (855)859-2056; international participants may dial (404)537-3406.  The conference ID for the replay is 64577060. The audio replay will be available until May 27th, 2013. 

About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510-856-5598.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCalls Microscope
2. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
3. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
4. Anthera to Report Second Quarter 2012 Financial Results
5. Life Technologies Announces First Quarter 2013 Results
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
8. BioLife Solutions Announces License Agreement
9. PRIM&R Announces Longtime Leader to Step Down
10. MiMedx Announces Record First Quarter 2013 Results
11. ViroPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Leading ... clinical study of its canine osteoarthritis stem cell product, currently under development for ... KS) and will be marketed in the US by Aratana. This product, termed ...
(Date:7/30/2015)... 2015 HIGHLIGHTS:Q2 2015 Results (all ... , Reported sales were $697 million compared to $701 ... organically by 8%, and changes in foreign currency exchange ... by 1%. , By business unit, organic sales ... 11% in SAFC Commercial. , Reported diluted EPS ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), ... healthcare services, offering both facility-based and home-based post-acute ... the second quarter ended June 30, 2015. ... volume growth in both segments and an 11.0% ... President and Chief Executive Officer of HealthSouth. "While ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... operate efficiently and last a long time is a big ... the assembly line. The precious metal platinum has been the ... It is expensive, and it breaks down over time in ... University report a promising advance. They have created a unique ...
... MARINO, Calif. , May 24 Epeius Biotechnologies ... the study entitled "A Phase I/II Study of Intravenous Rexin-G ... ASCO Annual Meeting on June 6, 2010 . The ... , Chairman of the Cancer Institute and Bioethics Committee-Philippine General ...
... 24 Newport Corporation (Nasdaq: NEWP ) today announced that it ... 25, 2010 , at 3:30 pm Pacific time (6:30 pm ... of Loews Santa Monica Beach Hotel in Santa Monica, Calif. , ... The 25-minute presentation by Senior Vice President ...
Cached Biology Technology:Brown chemists report promising advance in fuel-cell technology 2Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010) 2Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010) 3Newport Corporation to Present at B. Riley & Co. Investor Conference Tomorrow, May 25 2
(Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/8/2015)... The consumer products industry for innovative ... products such as wearables, smart wallets & other smart technology ... devices continues to rapidly grow.  Biometrics & Wearable Device Companies ... Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: BIDU ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... 11, 2013 Men tend to store fat in the ... of hips or thighs. Women, on the other hand, are ... than in the belly. Why are women and men shaped ... worth investigating, says Steven R. Smith, M.D., director of the ...
... , An internationally recognized expert in viruses, Robert W. ... and chair and professor of medicine at the University ... $12 million project to develop new ways of predicting ... to anti-viral drugs and the human immune system. This ...
... plants is short. They grow for around three to four ... also limited, with plants only growing to about one-and-a-half to ... Molecular Biology and Applied Ecology IME in Mnster have located ... they can keep it forever young. The Mnster-based researchers discovered ...
Cached Biology News:How belly fat differs from thigh fat -- and why it matters 2Giant tobacco plants that stay young forever 2
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Parathyroid Hormone Receptor 2 [PTHR2]...
... Zeba Desalt Spin Columns contain a proprietary ... offers exceptional desalting and protein-recovery characteristics compared ... as low as 25 g/ml of protein ... and > 95% retention of salts and ...
Biology Products: